Regeneron (REGN) Reports Positive 84-Week OPTIMA Trial Results f

Regeneron Pharmaceuticals reported 84-week Phase III trial data for Pasatru in adults with fibrodysplasia ossificans progressiva (FOP). The trial showed Pasatru prevented new heterotopic ossification lesions and reduced flare-ups compared to placebo. Safety data remained consistent, with no deaths reported. Regulatory submissions are planned in several countries, including Japan.

Regeneron (REGN) reported 84-week data from the Phase 3 OPTIMA trial, showing Pasatru prevented new HO lesions in FOP patients. The trial met primary endpoints, with no new lesions from Week 56 to 84. Pasatru also reduced flare-ups and had a well-tolerated safety profile. REGN plans to start a Phase 3 study in children with FOP. REGN stock closed at $762.81, up 2.18%.

Regeneron Pharmaceuticals (Nasdaq: REGN) reported 84-week Phase III trial results for Pasatru (garetosmab-grts) in treating fibrodysplasia ossificans progressiva (FOP). The data showed sustained efficacy in stopping new bone growth and reducing flare-ups. REGN shares closed up 2.2% at $762.81 after the announcement. The findings were presented at the ASBMR Annual Meeting.

Regeneron announced 84-week results from its Phase 3 OPTIMA trial for Pasatru in adults with FOP, showing sustained efficacy in halting new bone growth and reducing flare-ups. The trial met its primary endpoint at 56 weeks and maintained results at 84 weeks. Pasatru was recently FDA-approved based on 56-week data. Regeneron plans to start a Phase 3 trial for adolescents and children with FOP later this year.

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.

Regeneron Pharmaceuticals reported 84-week trial data for Pasatru, showing sustained efficacy in treating fibrodysplasia ossificans progressiva. Compared to placebo, Pasatru had fewer new lesions and flare-ups. Common side effects included acne and epistaxis. The FDA approved Pasatru based on 56-week data, and a regulatory review is ongoing in Europe. Regeneron plans a Phase 3 trial in younger patients later this year.